SCHEDULE: Eventide Asset Management Discloses 7.3% Stake in Ovid Therapeutics

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 12,773,577 shares, representing 7.3% of Ovid Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Eventide Asset Management, LLC, through its investment in the Eventide Healthcare & Life Sciences Fund, beneficially owns 12,773,577 shares of Ovid Therapeutics Inc. common stock.
• This holding represents 7.3% of the outstanding common stock of Ovid Therapeutics Inc. as of March 31, 2026.
• The filing is made by Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John.
• Eventide Asset Management, LLC is identified as an investment adviser.
• Finny Kuruvilla, M.D., Ph.D. and Robin C. John are identified as 'HC, IN' (likely indicating investment advisor or similar roles).
• The reporting persons disclaim beneficial ownership of the securities, stating they are held in the ordinary course of business and not for the purpose of influencing control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates a significant passive investment but provides no new operational or financial information about Ovid Therapeutics Inc.

Positives

• Significant stake of 7.3% held by Eventide Asset Management, LLC, indicating investor confidence.
• The filing is routine for a substantial shareholder, suggesting normal business operations rather than a hostile takeover or activist campaign.

Negatives

• The filing does not contain any financial performance data or operational updates, limiting the assessment of the company's current health.
• The disclaimer of beneficial ownership by individuals may suggest a complex ownership structure or a desire to limit liability.

Risks

• The primary risk is the inherent volatility of biotechnology and pharmaceutical stock prices, which can be influenced by clinical trial results, regulatory approvals, and market sentiment.
• As a Schedule 13G filing, it indicates a passive investment, meaning Eventide is not actively seeking to influence management or strategy, which could be a risk if the company requires strategic direction.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Ovid Therapeutics Inc.'s future performance.

Management Comments

• Each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as disclosed in this Schedule 13G filing by Eventide Asset Management, is common in the biotechnology sector. Such filings often signal a belief in the company's long-term potential, particularly for companies in clinical development stages.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's passive stake, which can be viewed positively as a sign of confidence in the company's long-term prospects.
• Management: The filing does not indicate any immediate pressure from Eventide for strategic changes, allowing current management to proceed with existing plans.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• Eventide Asset Management, LLC will continue to hold its shares in Ovid Therapeutics Inc. as an investment adviser.
• Ovid Therapeutics Inc. will continue its operations, subject to market conditions and its own strategic initiatives.

Key Dates

Keywords

Ovid Therapeutics, Schedule 13G, Eventide Asset Management, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals